{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:59:52Z","timestamp":1790269192949,"version":"4.1.0"},"reference-count":15,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.25065","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:08:12Z","timestamp":1769638092000},"page":"63-68","source":"Crossref","is-referenced-by-count":4,"title":["Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma"],"prefix":"10.3960","volume":"66","author":[{"given":"Akihiro","family":"Kawatsuki","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji-shi, Hyogo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji-shi, Hyogo, Japan,"},{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoka","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Japanese Red Cross Society Himeji Hospital, Himeji-shi, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Fushimi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Japanese Red Cross Society Himeji Hospital, Himeji-shi, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji-shi, Hyogo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji-shi, Hyogo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji-shi, Hyogo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji-shi, Hyogo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji-shi, Hyogo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Lesokhin AM, Tomasson MH, Arnulf B <i>et al.<\/i> Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023; 29: 2259-2267.","DOI":"10.1038\/s41591-023-02528-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Wang J, Hu Y, Yang S <i>et al.<\/i> Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019; 25: 1092-1098.","DOI":"10.1016\/j.bbmt.2019.02.008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Imataki O, Uemura M, Fujita H, Kadowaki N. Pathological landscape of tumor flare reaction to epcoritamab treatment. Int J Hematol. 2024; 120: 467-471.","DOI":"10.1007\/s12185-024-03833-w"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Forsberg M, Beltran S, Goldfinger M <i>et al.<\/i> Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma. Haematologica. 2024; 109: 2368-2371.","DOI":"10.3324\/haematol.2023.284436"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Van de Wyngaert Z, Romera-Martinez I, Chedeville C <i>et al.<\/i> Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis. Clin Hematol Int. 2024; 6: 46-50.","DOI":"10.46989\/001c.116800"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Nagarajan C, Eu Jo MW, Martin TG III. BCMA directed bispecific antibody induced tumor flare in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024; 24: 488-490.","DOI":"10.1016\/j.clml.2024.03.002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Fujita M, Okamoto S, Jinnouchi K <i>et al.<\/i> Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction. Int J Hematol. 2025; 122: 148-152.","DOI":"10.1007\/s12185-025-03979-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Crombie JL, Graff T, Falchi L <i>et al.<\/i> Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood. 2024; 143: 1565-1575.","DOI":"10.1182\/blood.2023022432"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Khan AM, Kroog GS, Roccia T <i>et al.<\/i> Radiologic Pseudoprogression Associated With a Positive Response in a Patient With Multiple Myeloma Treated With a BCMA\u00d7CD3 Bispecific Antibody: A Case Report. EJHaem. 2025; 6: e70168.","DOI":"10.1002\/jha2.70168"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Imataki O, Uchida S, Uemura M. Metabolic pitfall of pseudoprogression after epcoritamab treatment. EJHaem. 2024; 5: 1346-1347.","DOI":"10.1002\/jha2.1026"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Lee DW, Gardner R, Porter DL <i>et al.<\/i> Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124: 188-195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Neelapu SS, Tummala S, Kebriaei P <i>et al.<\/i> Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15: 47-62.","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Suyama T, Yui T, Horiuchi A <i>et al.<\/i> Transient atelectasis due to hilar lymph node swelling affected by lenalidomide-induced tumor flare reaction. J Clin Exp Hematop. 2021; 61: 48-52.","DOI":"10.3960\/jslrt.20045"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Costa BA, Flynn J, Nishimura N <i>et al.<\/i> Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 2024; 14: 84.","DOI":"10.1038\/s41408-024-01048-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Davis JA, Snyder J, Rice M <i>et al.<\/i> Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed\/refractory multiple myeloma. Blood Cancer J. 2025; 15: 32.","DOI":"10.1038\/s41408-025-01222-y"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/1\/66_25065\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:31:23Z","timestamp":1775277083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/1\/66_25065\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25065","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"25065"}}